Financial Data and Key Metrics Changes - Total revenues for Q2 2022 were $18.5 million, down from $25.8 million in Q2 2021, reflecting a significant decline [22] - Gross margin decreased to 35.3% from 42.7% in Q2 2021, primarily due to reduced demand for COVID-related products [23] - Operating loss for Q2 2022 was $1.4 million compared to an operating profit of $200,000 in Q2 2021 [27] - Net financial expenses increased to $8.3 million in Q2 2022 from $0.3 million in Q2 2021, largely due to early repayment penalties and higher interest rates [28] Business Line Data and Key Metrics Changes - Excluding COVID-related products, revenues for Q2 2022 were approximately $18 million, flat compared to Q2 2021, but up 7% from Q1 2022 [38] - The diabetes A1c product line saw a year-over-year revenue increase of over 25% [38] - Fitzgerald Life Science business experienced a 25% quarter-over-quarter growth [39] Market Data and Key Metrics Changes - Preliminary estimates for Q3 2022 revenues are expected to be between $19 million to $20 million, driven by double-digit year-over-year increases in hemoglobins and Fitzgerald Life Science businesses [39] - HIV point-of-care revenue is anticipated to grow over 30% on a quarter-over-quarter basis due to increased orders from Africa [40] Company Strategy and Development Direction - The company aims to establish a clear vision and strategy focusing on scaling core businesses, particularly in point-of-care and lab services [15] - There is a renewed focus on inorganic growth through partnerships and M&A to scale operations [17] - The company plans to leverage its Fitzgerald brand and optimize its hemoglobins business for profitability [15][47] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the fluid situation regarding COVID-19 and its impact on product sales, particularly PCR testing [60][61] - The company is not relying on COVID-related products as a driver of future strategy [60] - Management is optimistic about growth potential in the autoimmune business and plans to invest significantly in the decentralized testing market [49][52] Other Important Information - The company received a $45.2 million investment from MiCo Group, which includes equity and a convertible note [44] - An early repayment of $35 million of the term loan is expected to save $5 million in annual cash interest expenses [45] - The company is undertaking a portfolio-wide capital and talent allocation review to maximize returns [55] Q&A Session Summary Question: What is the outlook for sales of COVID-related products? - Management indicated that sales have significantly declined and are not expected to be a major part of future strategy [60][61] Question: How should interest expenses be viewed for the upcoming quarters? - Interest on the Perceptive debt is approximately 14%, with expected cash interest costs based on the remaining balance [68] Question: What is the expected share count for the third quarter? - The share count is expected to increase due to shares issued to MiCo being outstanding for a longer period [69] Question: What is the market size for the new variant instrument? - The market for the variant product is expected to generate over $5 million to $6 million in revenue annually, primarily in the U.S. [84] Question: What is the company's strategy regarding potential partnerships? - The company is exploring partnerships with both younger tech companies and traditional CPG companies to enhance its market position [94][96]

Exhibit 99.1 Press Release dated June 30, 2022 Contact:Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Quarter 1 2022 Financial Results DUBLIN, Ireland (June 30, 2022)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended March 31, 20 ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2022 Earnings Conference Call June 30, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan OÂ'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is being ...

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Exhibit 99.1 Press Release dated April 11, 2022 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results DUBLIN, Ireland (April 11, 2022)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended Decembe ...

Exhibit 99.1 September 30, 2021 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Results of AGM Dublin, Ireland (September 30, 2021)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results of the Annual General Meeting (AGM). AGM Results On September 29, 2021 Trin ...

Trinity Biotech plc (NASDAQ:TRIB) Q2 2021 Earnings Conference Call September 9, 2021 11:00 AM ET Company Participants Joe Diaz - Lytham Partners Ronan OÂ'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Paul Nouri - Noble Equity Funds Operator Good morning, everyone. And welcome to the Trinity Biotech Q2 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instr ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2021 Results Conference Call May 25, 2021 11:00 AM ET Company Participants Joe Diaz - Lytham Partners Ronan OâCaoimh - CEO John Gillard - CFO Conference Call Participants Paul Nouri - Noble Equity Funds Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After todayâs presentation, there will be an opportunity to ask que ...

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Trinity Biotech plc (NASDAQ:TRIB) Q4 2020 Results Conference Call March 26, 2021 11:00 AM ET Company Participants Ronan O’Caoimh - CEO John Gillard - CFO Conference Call Participants Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the Trinity Biotech Q4 and Fiscal Year 2020 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator instructions] Please note, th ...